Aug 6, 2026 06:30AM
Aug 3, 2026 07:01AM
Aug 3, 2026 07:00AM
Jun 16, 2026 07:01AM
Jun 16, 2026 07:00AM
Jun 9, 2026 03:54AM
Jun 8, 2026 08:34PM Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
May 11, 2026 07:00AM
May 11, 2026 07:00AM
Apr 17, 2026 03:01PM
Apr 17, 2026 03:01PM
Apr 1, 2026 07:30AM
Apr 1, 2026 07:30AM
Feb 26, 2026 07:00AM Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM
Nov 6, 2025 07:00AM
Oct 24, 2025 09:00AM
Oct 24, 2025 09:00AM
Oct 13, 2025 12:02PM
Oct 13, 2025 12:02PM Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Sep 2, 2025 05:01AM
Sep 1, 2025 08:00PM
Aug 7, 2025 06:00AM
Jun 2, 2025 07:01AM
Jun 2, 2025 07:00AM
May 31, 2025 03:08PM
May 19, 2025 07:02AM Zai Lab (ZLAB) Receives U.S. FDA Fast Track Designation for ZL-1310
May 19, 2025 07:00AM
May 8, 2025 06:00AM
Apr 23, 2025 10:56AM
Apr 21, 2025 07:30AM
Apr 21, 2025 07:30AM
Mar 12, 2025 07:30PM
Feb 27, 2025 06:00AM Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
Jan 22, 2025 11:16PM
Jan 22, 2025 11:15PM
Jan 17, 2025 07:30AM
Jan 17, 2025 07:30AM
Jan 15, 2025 07:30AM
Jan 15, 2025 07:30AM
Nov 27, 2024 11:05PM Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Nov 21, 2024 04:00AM
Nov 12, 2024 06:30AM
Sep 27, 2024 08:05AM
Aug 6, 2024 04:05PM
Jul 16, 2024 12:15AM
May 20, 2024 05:54AM
May 20, 2024 12:21AM Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Ba
May 13, 2024 05:47AM

328,607 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All